Annalice Gandini/LinkedIn
Jul 5, 2025, 17:20
Annalice Gandini: Our Poster on the Safety and Efficacy of Encorafenib Plus Panitumumab in mCRC at ESMOGI25
Annalice Gandini, Fellow at Cordeliers Research Center, shared a post on LinkedIn:
“Happy to share our poster presenting real-world data on the safety and efficacy of encorafenib plus panitumumab in BRAF V600E mutated mCRC patients who experienced severe toxicity with cetuximab. ORR, PFS and OS are comparable to those reported in the BEACON trial, supporting this combination as a potential option in patients unable to continue cetuximab.”
More posts featuring Annalice Gandini.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 20:31
Jul 5, 2025, 20:15
Jul 5, 2025, 20:00
Jul 5, 2025, 19:18
Jul 5, 2025, 18:52
Jul 5, 2025, 18:38